welcome to OncLive on the air®! I’m your host today, Caroline Seymour.

OncLive on the air® is a podcast by Live®, which provides oncology professionals with the resources and information they need to provide the best patient care. In digital and printed format, Live® covers all aspects of oncology practice, from new technologies to therapeutic advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Vivek Subbiah, MD about the data presented at the 2022 ASCO Annual Meeting that caught his attention. Dr. Subbiah is Associate Professor in the Department of Experimental Cancer Therapy and Clinical Medical Director of the Clinical Center for Targeted Therapy, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center.

In our exclusive interview, Dr. Subbiah discussed the results of 4 presentations that stood out for him: Phase 2 data (NCT04165772) demonstrating a 100% complete response rate in 12 patients with rectal cancer locally advanced and deficient in mismatch repair who received dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “significant and practice-changing” for patients with unresectable and/or metastatic HER2-low breast cancer; a first-in-human study (NCT04585750) of PC14586, a novel agent targeting TP53 in advanced solid tumors; and the LIBRETTO-001 trial (NCT03157128), which demonstrated that selpercatinib (Retevmo) can target RET-positive fusions in solid tumors.

That’s all we have for today! Thanks for listening to this episode of OncLive on the air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology.

For more oncology updates, be sure to visit www.OncLive.com and sign up for our e-newsletters.

Live® is also on social media. On Twitter, follow us on @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive on the air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms*, to receive a notification whenever a new episode is released. While you’re at it, please take a moment to rate us!

Thanks again for listening OncLive on the air®.

*OncLive on the air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.